News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dimerix Bioscience and Takeda Pharmaceutical Co. Ltd. (TKDG.DE) Sign Agreement to Use GPCR-HIT Platform in Discovery Program


4/20/2010 9:09:57 AM

PERTH, Australia--(BUSINESS WIRE)--Dimerix Bioscience Pty Ltd, a pre-clinical stage product company developing a pipeline of ’best in class’ lead products with highly specific activity and with reduced risk of off-target effects, today announced that it has entered into a research agreement with Takeda Cambridge Limited, a UK based subsidiary of Takeda Pharmaceutical Company Limited, Japan’s largest pharmaceutical company.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES